Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price6.09 USD
Fair valueUnder review
Ethical score30.0/100
Our investment reviews on this name
2026-10-11Read Markdown9.61-36.6% to today ✓Accumulation gives way to Markdown first Markdown read since September
2026-10-02Read Accumulation9.61-36.6% to today Markdown gives way to Accumulation after an 8% slide in 6 weeks
2026-08-19Read Markdown10.42-41.6% to today ✓Markup gives way to Markdown after a 62% slide in 7 weeks
2026-07-02Read Markup27.69-78.0% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
York Space Systems, Inc. holds its Markdown at $6.09. The statistical read favours the sellers, held for 51 days.
As held on the ledger · 2026-11-04
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 51 days
Price at the screen
$6.09
Valuation
N/A trailing · -17.96 forward price to earnings
Values screen
FAIL· score 30.0
The Workings
Five Screens, Shown in Full
Does not pass. Prohibited business activity: Aerospace & Defense
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Prohibited business activity: Aerospace & Defense
Fail
Debt load
Excluded
Below 33%
Interest-bearing debt is of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
Excluded
Below 33%
Interest-bearing cash and securities are of assets, above the one-third limit.
Fail
Receivables
Excluded
Below 49%
Money owed to the company is of assets, above the 49% limit.
Fail
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
York Space Systems, does not clear the screen at the business-activity stage. It operates in aerospace and defense, so the financial ratios are not the deciding factor here.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when YSS's ethical verdict changes
Today YSS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Fair value under review. Our model's value is 2.30x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Defence satellites fail the ethical screen outright
York Space Systems builds satellites and software for national security work that governments cannot do without. The numbers show revenue edging up 10 percent but margins stuck at minus 47 percent and a forward multiple of 33.6 times earnings. That combination already looks stretched even before the ethical verdict lands.
We pass for one clear reason. The business sits squarely inside prohibited aerospace and defence activity, which our screen rejects without debate. Analyst targets above thirty dollars and a modest stated margin of safety change nothing once that line is crossed.
The real exposure sits in thin profitability and heavy reliance on government budgets that can shift with policy. This is exactly what the screen is for. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
YSS trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markdown$6.09-3.6%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 3.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (9 analysts) rates it buy, with a mean price target of $35. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markdown$6.32+6.2%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 6.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (9 analysts) rates it buy, with a mean price target of $35.
2026-10-25Markdown$5.95+0.0%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (9 analysts) rates it buy, with a mean price target of $35.
2026-10-18Markdown$5.95-38.1%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 38.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (9 analysts) rates it buy, with a mean price target of $35.
2026-10-11Markdown · changed$9.61+0.0%Entry 7
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (9 analysts) rates it buy, with a mean price target of $35.
2026-10-02Accumulation · changed$9.61+7.3%Entry 6
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 7.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (9 analysts) rates it buy, with a mean price target of $35.
2026-09-18Markdown$8.96-14.0%Entry 5
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 14.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (9 analysts) rates it buy, with a mean price target of $35.
2026-08-19Markdown · changed$10.42-62.4%Entry 4
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 62.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (9 analysts) rates it buy, with a mean price target of $35.
2026-07-18Markup$27.69+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (9 analysts) rates it buy, with a mean price target of $35.
2026-07-03Markup$27.69+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.